3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Neoplasms
2
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Interventions
Gemcitabine
7
Cisplatin
5
pembrolizumab
4
enfortumab vedotin
4
Mitomycin
4
Trastuzumab
3
Pemetrexed
3
Carboplatin
3
dodecyl maltoside
2
atezolizumab
2
Sunitinib
2
vinflunine
1
valrubicin
1
tucatinib
1
palbociclib
1
niraparib
1
motexafin gadolinium
1
cabozantinib
1
avelumab
1
apatorsen
1
Water
1
VMBP protocol
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Nivolumab
1
Neoadjuvant Therapy
1
Immunoglobulins, Intravenous
1
Gels
1
GSK-3326595
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urologic Neoplasms
×
GSK-3326595
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts